Register Login
Register to leave comments
  • News bot Dec. 17, 2025, 4:11 p.m.

    📋 Nuo Therapeutics, Inc. (AURX) - Regulatory Update

    Filing Date: 2025-12-17

    Accepted: 2025-12-17 11:09:26

    Event Type: Regulatory Update

    Event Details:

    Nuo Therapeutics, Inc. (AURX) Announces Regulatory Update Nuo Therapeutics, Inc. (AURX) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (Nuo Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Non- immersive virtual reality (niVR)-based telerehabilitation home program DEVICE Approved Stroke ClinicalTrials.gov
    High dose combination DRUG Phase PHASE2 Gout ClinicalTrials.gov
    400 mg Allopurinol DRUG Phase PHASE2 Gout ClinicalTrials.gov
    Combination - Tranilast and Allopurinol DRUG Phase PHASE2 Gout ClinicalTrials.gov
    Allopurinol DRUG Phase PHASE2 Gout ClinicalTrials.gov
    Tranilast DRUG Phase PHASE2 Gout ClinicalTrials.gov
    Combination - Tranilast and Febuxostat DRUG Phase PHASE2 Gout ClinicalTrials.gov
    Febuxostat DRUG Phase PHASE2 Gout ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Active Rheumatoid Arthritis ClinicalTrials.gov
    Combination 600 DRUG Phase PHASE2 Moderate to Severe Gout ClinicalTrials.gov
    Combination 400 DRUG Phase PHASE2 Moderate to Severe Gout ClinicalTrials.gov
    Placebo comparator DRUG Phase PHASE1 Rheumatoid Arthritis ClinicalTrials.gov
    Aurix DEVICE Approved Diabetic Foot Ulcers ClinicalTrials.gov
    MemorEM DEVICE Phase PHASE1 Alzheimer's Disease ClinicalTrials.gov
    MemorEM 1000 DEVICE Approved Alzheimer Disease ClinicalTrials.gov
    Alpress LP DRUG Phase PHASE2 Alcohol Use Disorder ClinicalTrials.gov
    Cyproheptadine DRUG Phase PHASE2 Alcohol Use Disorder ClinicalTrials.gov
    Autograft(ing) PROCEDURE Phase PHASE3 Burns Degree Third ClinicalTrials.gov
    Skin Xenotransplant DRUG Phase PHASE3 Burns Degree Third ClinicalTrials.gov
    Needle based delivery of INT001 into liver tumors under real-time image guidance DEVICE Approved Liver Tumors ClinicalTrials.gov
    KT110 DRUG Phase PHASE1 Alcohol Use Disorder ClinicalTrials.gov
    Prazosin + cyproheptadine DRUG Phase PHASE1 Alcohol Use Disorder ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: Nuo Therapeutics, Inc.
    • CIK: 0001091596
    • Ticker Symbol: AURX
    • Period End Date: 2025-12-16
    • Document Type: 8-K

Search

News categories